Ani Pharmaceuticals, Inc last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $290.8 million (+27.6% year over year) and diluted EPS of $1.51. It usually reports 12–38 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–38 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
291
+27.6%
|
35
+32.1%
|
1.51
+33.6%
|
|
Aug 7, 2026
38 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
266
+25.9%
|
25
+189.1%
|
1.05
+191.7%
|
|
May 8, 2026
38 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
237
+20.5%
|
29
+88.1%
|
1.28
+85.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
247
+29.6%
|
27
+367.5%
|
1.46
+365.7%
|
|
Nov 7, 2025
38 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
228
+53.6%
|
27
+210.1%
|
1.13
+189.0%
|
|
Jul 23, 2025
23 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
211
+53.1%
|
9
+473.8%
|
0.36
+357.1%
|
|
May 9, 2025
39 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
197
+43.4%
|
16
-13.9%
|
0.69
-15.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
191
+44.8%
|
-10
-989.7%
|
-0.55
-1514.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANIP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1023024
- Former names
- BIOSANTE PHARMACEUTICALS INC (until Jul 18, 2013); BEN ABRAHAM TECHNOLOGIES INC (until Dec 23, 1999)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.